☆ 4.4 Article

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae : Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Omic insights into various ceftazidime-avibactam-resistant Klebsiella pneumoniae isolates from two southern Italian regions

Dafne Bongiorno et al.

Summary: This study reports the emergence of ceftazidime-avibactam resistance in Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria in Italy. Genomic analysis revealed the presence of multiple resistance genes and different KPC enzyme variants. Mutations in membrane permeability genes were identified as a potential mechanism underlying carbapenem resistance. Accurate detection methods for KPC enzymes are urgently needed.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

添加到收藏夹

Editorial Material Infectious Diseases

Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report

Gabriele Arcari et al.

Summary: The aim of this study was to investigate ceftazidime-avibactam resistant and susceptible Klebsiella pneumoniae strains isolated from a patient with SARS-CoV2. The patient's condition, antimicrobial therapies, and microbiological data were collected. The study found the presence of highly conserved ST2502 strains producing KPC-31 and KPC-3, selected by CZA and carbapenem treatments, respectively, in the patient.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Oncology

Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes

Gabriele Bianco et al.

Summary: This study found that the majority of Gram-negative bacteria showed high susceptibility to ceftazidime-avibactam (CZA), amikacin, and meropenem. ESBL-producing Enterobacterales also exhibited high susceptibility to CZA, carbapenems, and ceftolozane-tazobactam. Meropenem-vaborbactam displayed the highest activity against KPC-producing Enterobacterales.

JOURNAL OF CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

The Genomic Characterization of KPC-Producing Klebsiella pneumoniae from the ICU of a Teaching Hospital in Shanghai, China

Yingying Du et al.

Summary: This study retrospectively analyzed the genome characteristics of blaKPC-2 in multidrug-resistant Klebsiella pneumoniae collected from a teaching hospital in Shanghai, China. The results showed that blaKPC-2 gene is relatively conservative in evolution, and there are significant differences in the plasmid-encoded region. The coexistence of blaKPC-2 with fosA6 or blaCTX-M variants is associated with increased resistance.

INFECTION AND DRUG RESISTANCE (2022)

添加到收藏夹

Article Infectious Diseases

In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects

Gabriele Bianco et al.

Summary: The study assessed the in vitro activity of cefiderocol against both ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales. Results showed a significantly higher resistance rate in CZA resistant isolates, with CFDC showing synergistic effects mainly with CZA.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Infectious Diseases

Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)

Giusy Tiseo et al.

Summary: The management of infections caused by multidrug-resistant organisms is challenging and requires a multidisciplinary approach. This paper provides recommendations for the diagnosis and optimal management of these infections, with a focus on targeted antibiotic therapy. However, the available evidence is limited, and some recommendations are based on low certainty. These recommendations should be regularly updated.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Letter Infectious Diseases

Evaluation of synergistic activity of fosfomycin in combination with novel β-lactams/β-lactamase inhibitor combinations (βL-βLICs) against KPC-producing Klebsiella pneumoniae clinical isolates

Paolo Gaibani et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Engineering, Biomedical

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)

Tommaso Lupia et al.

Summary: Meropenem/vaborbactam and cefiderocol are promising antibacterials against multi-drug resistant gram-negative bacilli. A survey was conducted among infectious disease and intensive care unit physicians of Italian hospitals to gather data on their habits and prescriptions of these drugs. The results showed that both cefiderocol and meropenem/vaborbactam were mostly used as targeted therapy after treatment failure and specialist consultation. The most common multi-drug resistant pathogen in hospitals was Klebsiella pneumoniae carbapenemase-producing bacteria.

JOURNAL OF FUNCTIONAL BIOMATERIALS (2022)

添加到收藏夹

Review Infectious Diseases

Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)

Giusy Tiseo et al.

Summary: Managing infections caused by multidrug-resistant organisms requires a multidisciplinary approach, with a focus on targeted antibiotic therapy. Recommendations were developed by experts nominated by Italian societies, with classifications based on the certainty of evidence, although some recommendations have low certainty due to limited clinical trial data.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Infectious Diseases

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study

I Karaiskos et al.

Summary: The study demonstrates that ceftazidime/avibactam is effective in treating infections caused by KPC-Kp, significantly reducing mortality rates. Additionally, ultimately fatal disease, rapidly fatal disease, and Charlson comorbidity index ≥ 2 were identified as independent predictors of death, while treatment with ceftazidime/avibactam-containing regimens was the only independent predictor of survival.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Immunology

Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study

Mario Tumbarello et al.

Summary: The study found that there was no significant difference in 30-day mortality rates between patients treated with ceftazidime-avibactam alone and those treated with combination regimens for managing infections caused by carbapenem-resistant Enterobacteriaceae. Factors such as septic shock and neutropenia at infection onset were positively associated with mortality, while prolonged infusion of CAZ-AVI was negatively associated with mortality. Further research is needed to explore the potential survival benefits of prolonging CAZ-AVI infusions in certain types of infections.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series

S. A. van Asten et al.

Summary: This study describes the emergence of CZA resistance in KPC-producing Klebsiella pneumoniae and evaluates mutations responsible for the restoration of carbapenem susceptibility. During treatment, in vitro restoration of carbapenem susceptibility was observed in 3 isolates.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases

Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae

Carolina Venditti et al.

Summary: The study analyzed ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae strains collected from 31 patients in six hospitals in Rome, revealing mutations in KPC variants within the bla(KPC-3) gene and the presence of high-risk clones (ST512, 101, and 307). The findings highlight concerns over the potential selection of a multidrug-resistant phenotype in strains showing resistance to both ceftazidime-avibactam and carbapenems.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Letter Oncology

Looking beyond ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae: in vitro activity of the novel meropenem-vaborbactam in combination with the old fosfomycin

Boattini Matteo et al.

JOURNAL OF CHEMOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases

Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm

Lorenzo Volpicelli et al.

Summary: The global spread of antimicrobial resistance poses a major threat to global health and development, with infections by MDRO often leading to unfavorable outcomes. The emergence of new antimicrobial agents with potent activity against MDROs requires careful and strategic utilization to improve patient outcomes, especially in environments with high prevalence of MDROs and among critically ill populations.

ANTIBIOTICS-BASEL (2021)

添加到收藏夹

Article Immunology

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3

Giusy Tiseo et al.

Summary: A 68-year-old man had recurrent bacteremia caused by a K. pneumoniae strain producing the KPC-3 variant enzyme, resistant to ceftazidime-avibactam but susceptible to meropenem after treatment.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology

Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates

Alessandra Carattoli et al.

Summary: A study conducted in a university hospital in Rome, Italy identified multiple CZA-resistant KPC-3 protein variants, including novel variants that had not been reported before. These variants showed different sensitivities and activities to antibiotics, possibly due to mutations caused by amino acid substitutions, insertions, and deletions.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Microbiology

KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae

Jacqueline Findlay et al.

Summary: This study evaluated the impact of KPC variants on CZA resistance, finding increased susceptibility to cephalosporins and carbapenems but increased resistance to ceftazidime and piperacillin-tazobactam. The KPC variants exhibited increased affinity towards ceftazidime and slightly decreased sensitivity to avibactam, impacting CZA resistance while concurrently negatively impacting carbapenemase activities.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Immunology

Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae

Yingyi Guo et al.

Summary: This study identified a novel mechanism of CAZ-AVI resistance associated with mutations in the porin LamB in KPC-Kp strains.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Review Infectious Diseases

Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies

Stefano Di Bella et al.

Summary: Resistance to CAZ-AVI is emerging among KPC-E infections, primarily from K. pneumoniae ST258 with D179Y substitution. It poses a serious threat and requires close monitoring due to high infection rates and severity of the condition.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside

Alessandra Oliva et al.

Summary: This challenging case highlights the possibility of CZA underexposure on the infected thrombus and the risk of in vivo emergence of CZA resistance in the setting of persistent bacteremia and sub-optimal anticoagulation. Pharmacokinetic analyses showed that both MVB and FOS were in the therapeutic range, with in vitro studies demonstrating a high level of MVB + FOS synergism allowing definitive resolution of the endovascular infection.

ANTIBIOTICS-BASEL (2021)

添加到收藏夹

Article Infectious Diseases

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China

P. Zhang et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

添加到收藏夹

Article Infectious Diseases

Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization

P. Gaibani et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

添加到收藏夹

Review Infectious Diseases

Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature

Angela Cano et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)

添加到收藏夹

Article Microbiology

Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam

Ruslan Tsivkovski et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Article Microbiology

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Renee Ackley et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Review Infectious Diseases

Resistance to ceftazidime-avibactam and underlying mechanisms

Yuhang Wang et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)

添加到收藏夹

Review Infectious Diseases

Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies

Roberta Maria Antonello et al.

ANTIBIOTICS-BASEL (2020)

添加到收藏夹

Review Immunology

Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations The Price of Progress

Krisztina M. Papp-Wallace et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)

添加到收藏夹

Review Infectious Diseases

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam

Eric Wenzler et al.

INFECTIOUS DISEASES AND THERAPY (2020)

添加到收藏夹

Article Immunology

Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae

Mario Tumbarello et al.

CLINICAL INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Microbiology

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

添加到收藏夹

Article Infectious Diseases

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Belen Gutierrez-Gutierrez et al.

LANCET INFECTIOUS DISEASES (2017)

添加到收藏夹

Review Immunology

Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature

Ryan K. Shields et al.

OPEN FORUM INFECTIOUS DISEASES (2017)

添加到收藏夹

Article Microbiology

In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases

Ryan K. Shields et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

添加到收藏夹

Article Microbiology

Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases

Ghady Haidar et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

添加到收藏夹

Review Immunology

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

David van Duin et al.

CLINICAL INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Microbiology

In Vitro Interactions of Antimicrobial Combinations with Fosfomycin against KPC-2-Producing Klebsiella pneumoniae and Protection of Resistance Development

Maria Souli et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)

添加到收藏夹

Letter Infectious Diseases

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

Olaf Burkhardt et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.